Back to Multiple Sclerosis
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00622700

NCT00622700
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have had your first clear neurological episode (such as optic neuritis diagnosed by an eye doctor, problems with your spinal cord, or issues with balance/coordination) that doctors believe may be caused by damage to the protective coating of nerve fibers
  • Your symptoms started within the last 90 days before joining the trial
  • A recent MRI scan shows 2 or more spots (each at least 3mm in size) that are typical of multiple sclerosis (MS)

Who may not be able to join:

  • You have a serious ongoing condition affecting your heart, liver, nervous system, hormones, or another major part of your body
  • You have significant problems with your bone marrow (the tissue inside bones that makes blood cells)
  • You are currently pregnant or breastfeeding
  • You have issues with alcohol or drug misuse
  • You have previously taken certain medicines that suppress the immune system, including cladribine, mitoxantrone, azathioprine, cyclophosphamide, cyclosporin, methotrexate, or mycophenolate
  • In the opinion of the trial doctor, there is any reason you may not be able to follow through with or complete the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Sanofi
Registry
clinicaltrials_gov
Start date
1 February 2008
Est. completion
1 December 2012

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇱 Chile 🇨🇿 Czechia 🇩🇰 Denmark 🇪🇪 Estonia 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇭🇺 Hungary 🇱🇹 Lithuania 🇲🇽 Mexico 🇵🇱 Poland 🇷🇴 Romania 🇷🇺 Russia Turkey (Türkiye) 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov